Clinical Cancer Research Versailles No Abst Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otake, S.
Right arrow Articles by Kawata, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otake, S.
Right arrow Articles by Kawata, S.
Clinical Cancer Research Vol. 11, 3642-3646, May 15, 2005
© 2005 American Association for Cancer Research

Human Cancer Biology

Association of Visceral Fat Accumulation and Plasma Adiponectin with Colorectal Adenoma: Evidence for Participation of Insulin Resistance

Sayaka Otake1, Hiroaki Takeda1, Yasukuni Suzuki1, Tadahisa Fukui1, Shinichiro Watanabe1, Katsuyoshi Ishihama1, Takafumi Saito1, Hitoshi Togashi1, Tadashi Nakamura2, Yuji Matsuzawa2 and Sumio Kawata1

Authors' Affiliations: 1 Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan and 2 Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Osaka, Japan

Requests for reprints: Sumio Kawata, Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan. Phone: 81-23-628-5307; Fax: 81-23-628-5311; E-mail: kawata{at}med.id.yamagata-u.ac.jp.


   Abstract
Top
 Abstract
Patients and Methods
 Results
 Discussion
 References
 
Purpose: Colorectal carcinogenesis is thought to be related to abdominal obesity and insulin resistance. To investigate whether visceral fat accumulation contributes to colorectal carcinogenesis, we examined its accumulation and the levels of the adipose tissue–derived hormone adiponectin in Japanese patients with colorectal adenoma.

Experimental Design: Fifty-one consecutive Japanese patients ages ≥40 years and with colorectal adenoma were subjected to measurement of visceral fat area by computed tomography scanning and plasma adiponectin concentration. The patients also underwent the 75-g oral glucose tolerance test. Insulin resistance was calculated by the homeostasis metabolic assessment (HOMA-IR) method. The controls were 52 Japanese subjects ages ≥40 years and without colorectal polyp. Cigarette smokers and subjects who consumed alcohol (≥30 g ethanol/d) were excluded.

Results: The patients with colorectal adenoma showed significantly more visceral fat area and significantly less plasma adiponectin concentration in comparison with the controls [odds ratio (OR), 2.19; 95% confidence interval (95% CI), 1.47-3.28; P < 0.001 and OR, 0.24; 95% CI, 0.14-0.41; P < 0.001, respectively] by logistic regression analysis. HOMA-IR index was also associated with colorectal adenoma (OR 2.60; 95% CI, 1.20-5.64; P = 0.040). Visceral fat area and adiponectin were associated with adenoma number (1, 2, ≥ 3), the size of the largest adenoma (<10 and ≥10 mm), and adenoma histology (tubular and tubulovillous/villous).

Conclusions: These results suggest an association of visceral fat accumulation and decreased plasma adiponectin concentration with colorectal adenoma in Japanese patients. This study may offer a new insight to understanding the relationship of colorectal carcinogenesis with abdominal obesity and insulin resistance.

Key Words: colorectal cancer • abdominal obesity • HOMA-IR

A relationship between body mass index (BMI) and increased risk for colorectal cancer has been suggested, especially for males (1). Recent reports have shown that the risk of colorectal cancer is associated with abdominal obesity with hyperinsulinemia and insulin resistance (2, 3).

Intra-abdominal adipose tissue mass has been assessed by measuring visceral fat area (VFA, cm2) by computed tomography (CT) scanning at the umbilical level (4–6). The area of VFA on the CT scan was shown related to the waist-to-hip circumference ratio (7). Many reports have shown VFA association with insulin resistance, diabetes mellitus, dyslipidemia, hypertension, and coronary heart disease (4–9). However, there have been few studies addressing the association between measured values of VFA and colorectal adenoma and cancer.

The adipose tissue–derived peptide hormone adiponectin has been reported to correlate inversely with whole body adipose mass (10). A decrease in plasma adiponectin with visceral fat accumulation is associated with insulin resistance, diabetes mellitus, and coronary heart disease (11–13). Recently, a low plasma concentration of adiponectin has been thought to be associated with tissue inflammation (14–16) and cancer development (17, 18). However, there has been no report on the relationship of plasma adiponectin concentration with colorectal adenoma and cancer. To clarify the role of abdominal obesity and insulin resistance in colorectal carcinogenesis, we measured VFA and plasma adiponectin concentration in Japanese subjects with and without colorectal adenoma.


   Patients and Methods
Top
 Abstract
 Patients and Methods
Results
 Discussion
 References
 
Patient selection. Fifty-one consecutive Japanese patients ages ≥40 years and with histologically diagnosed colorectal adenoma were enrolled in this study. The patients underwent total colonoscopy during a voluntary health check-up or because of occult fecal blood loss at the Yamagata University Hospital and hospitals affiliated with the Osaka University between January 2001 and December 2001. Patients with hyperplastic polyps, cigarette smokers, and subjects consuming alcohol (≥30 g ethanol/d) were excluded from this study. Also excluded were those with a history of colectomy, gastrectomy, or colorectal polypectomy and those under dietary or drug treatment for diabetes mellitus. Three of the 51 patients had rectal adenoma. The controls were 52 consecutive Japanese subjects ages ≥40 years and without colorectal polyp or inflammatory bowel diseases, who underwent total colonoscopy because of a voluntary health check-up or occult fecal blood loss during the same period and at the same hospitals, with the same exclusion criteria. The controls were drawn from the same population as the patients with colorectal adenoma. The response rates for agreed participation in this study were 91% for cases and 87% for controls.

This study protocol was approved from the Yamagata University Faculty of Medicine Ethical Committee. Written informed consent was obtained in advance from all subjects.

Assays. A 75-g oral glucose tolerance test was done after the subjects had fasted overnight. A Teflon catheter was inserted into the antecubital vein for blood sampling, and samples were obtained for plasma glucose and free insulin concentrations in the basal period and after an oral glucose load at 30-minute intervals for 180 minutes. The subjects were classified as normal, impaired glucose tolerance, or diabetes mellitus in accordance with the WHO criteria (19). Insulin resistance was calculated by the homeostatic metabolic assessment (HOMA-IR) method as follows: HOMA-IR = fasting plasma insulin x fasting plasma glucose/405, whereas insulin is expressed in microunits/mL and glucose in mg/d (20). Venous blood for assay of plasma concentration of adiponectin was drawn from all subjects after overnight fasting. Plasma samples were kept at –80°C for subsequent assay. The plasma concentration of adiponectin was determined with a sandwich ELISA system (adiponectin ELISA kit, Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) as previously reported (10). Body weight and height were recorded, and body mass index (BMI, kg/m2) was used as a measure of obesity.

Measurement of visceral fat area. The intra-abdominal visceral fat area (VFA) was measured at the level of the umbilicus by CT scan according to a procedure previously described (21). The border of the intra-abdominal cavity was outlined on the CT image, and VFA was quantified using standard software. The CT measurements were made blinded to case status. The coefficient of variation of these measurements by a single observer was <1.5%, and that of variation for day-to-day measurements was <1%. All CT scans were carried out using a CT scanner (General Electric Co., Fairfield, CT) with the subjects in a supine position.

Statistics. Differences of age, gender, fasting glucose, and insulin concentration, oral glucose tolerance test status, HOMA-IR, BMI, VFA, and plasma adiponectin concentration between patients and controls were assessed by Wilcoxon rank sum test or {chi}2 test. The relationship of VFA or plasma adiponecin with colorectal adenoma was determined using a logistic regression method (SAS Software Release 8.2, SAS Institute, Inc., Cary, NC) to obtain the odds ratio (OR) and 95% confidence interval (95% CI). Continuous variables were used for age, BMI, HOMA-IR, VFA, and plasma adiponectin concentration. The association of adenoma number with VFA or adiponectin was assessed by the nonparametric Jonckheere test. The association of other tumor characteristics such as the largest size of adenoma and histology of the adenoma with VFA or adiponectin was assessed by Wilcoxon rank sum test. P < 0.05 was considered statistically significant.


   Results
Top
 Abstract
 Patients and Methods
 Results
Discussion
 References
 
Age was not significantly different between the patients (59 ± 7.3 years, mean ± SD) with colorectal adenoma and the controls (58 ± 7.1; Wilcoxon rank sum test; Table 1). The patient group consisted of 35 males and 16 females, whereas the control group had 34 males and 18 females. No difference in gender was observed between the patients and the controls ({chi}2 test). Fasting plasma glucose concentration was not different between the two groups. Fasting insulin concentration was not significantly different between the two groups, although it tended to be higher in patients with colorectal adenoma (8.5 ± 2.3 microunits/mL) than in controls (6.1 ± 1.8; P = 0.11). Oral glucose tolerance test status was also not different between the two groups (normal/impaired glucose tolerance/diabetes mellitus were 28:14:9 in patients and 36:11:5 in controls; {chi}2 test). However, HOMA-IR index was significantly higher in the patient than in controls (2.2 ± 0.7 versus 1.4 ± 0.5; P = 0.032). BMI was not significantly different between the patients (23.6 ± 2.9) with colorectal adenoma and the controls (22.8 ± 2.6), although there was a tendency to be higher in the patient group (P = 0.14).


View this table:
[in this window]
[in a new window]

  		Table 1. Baseline characteristics of Japanese patients with colorectal adenoma and controls (Wilcoxon rank sum test or {chi}2 test)

 
The mean of VFA was 98.9 ± 36.3 cm2 in patients with colorectal adenoma, whereas it was 66.6 ± 29.5 cm2 in controls (Fig. 1). This indicated significant accumulation of visceral adipose tissue in patients with colorectal adenoma (P < 0.001; Wilcoxon rank sum test). In addition, the mean of plasma adiponectin was 7.0 ± 2.6 µg/mL in patients, whereas it was 10.6 ± 2.5 in controls, indicating that plasma adiponectin concentration was significantly lower in patients with colorectal adenoma (P < 0.001). BMI, VFA, and plasma adiponectin showed high correlation with each other (BMI versus VFA, Pearson's correlation coefficient r = 0.683, P < 0.001; BMI versus adiponectin, r = – 0.600, P < 0.001; VFA versus adiponectin r = – 0.677, P < 0.001).



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A, comparison of VFA between Japanese patients with colorectal adenoma and controls in Japanese patients. VFA is significantly greater in the patients than in the controls (P < 0.001, Wilcoxon rank sum test). Bar, mean value of VFA in the patients and controls. B, comparison of plasma adiponectin concentration between Japanese patients with colorectal adenoma and controls. The adiponectin concentration is significantly lower in the patients than in the controls (P < 0.001, Wilcoxon rank sum test). Bar, mean value of plasma adiponectin concentration in the patients and controls.

 
The numbers of adenomas were 1 in 23 patients, 2 in 13, and ≥3 in 15. The size of the largest adenoma was <10 mm in 41 patients and ≥10 mm in 10 patients. The histology was that of tubular adenoma in 44 patients, tubulovillous in five patients, and villous in two patients.

Logistic regression analysis showed that both VFA and plasma adiponectin concentration were significantly associated with colorectal adenoma (OR, 2.19; 95% CI, 1.47-3.28; P < 0.001 and OR, 0.24; 95% CI, 0.14-0.41; P < 0.001, respectively; Table 2). HOMA-IR index was also associated with colorectal adenoma (OR, 2.60; 95% CI, 1.20-5.64; P = 0.040). These observations suggested an association of insulin resistance with colorectal adenoma.


View this table:
[in this window]
[in a new window]

  		Table 2. Factors associated with colorectal adenoma in Japanese patients assessed by logistic regression analysis

 
VFA and plasma adiponectin concentration were associated with tumor number (P < 0.01 and P < 0.05, respectively; Jonckheere test; Table 3). In addition, VFA and adiponectin were associated with the size of the largest adenoma (P < 0.01 and P < 0.01, respectively; Wilcoxon rank sum test) and the histology of the adenoma (P < 0.01 and P < 0.05, respectively; Wilcoxon rank sum test).


View this table:
[in this window]
[in a new window]

  		Table 3. Association of adenoma number, size of the largest adenoma, and histology of adenoma with VFA or plasma adiponectin concentration in Japanese patients with colorectal adenoma

 

   Discussion
Top
 Abstract
 Patients and Methods
 Results
 Discussion
References
 
Abdominal obesity, which is known to correlate strongly with visceral fat accumulation (4, 6), has been linked to cardiovascular disease (22), diabetes mellitus (5, 23), and overall mortality (24). Data have suggested that abdominal obesity might also be associated with colon (2, 3), breast (25), and prostate (26) neoplasia. Epidemiologic studies have shown an association between waist circumference and waist-to-hip ratio and colon neoplasia (2, 3).

In this study, we examined whether VFA is associated with colorectal adenoma in Japanese patients. The results suggested that visceral fat accumulation is a risk factor of colon adenoma. To our knowledge, this is the first report to show an association between measured VFA and colorectal adenoma. On the other hand, BMI was not significantly associated with colorectal adenoma. Schoen et al. (2) reported that higher levels of waist-to-hip circumference, but not BMI, were significantly associated with colorectal cancer. These data suggest that visceral adipose tissue rather than whole body adipose tissue is associated with colorectal adenoma.

Plasma adiponectin concentration is known to decrease with obesity, especially in abdominal obesity in association with insulin resistance (27–32) and atherosclerosis (12, 33). In this study, we showed that decrease in plasma adiponectin concentration is a factor associated with the development of colorectal adenoma in Japanese patients. Low concentration of plasma adiponectin may be a risk factor of colorectal adenoma. Adiponectin also seems to participate in regulating inflammation and apoptosis possibly via inhibition of nuclear factor {kappa}B signaling (14, 34). Recently, an association has been thought to exist between reduced adiponectin in blood and carcinogenesis (17, 18, 35). This study offers a new insight towards understanding the role of insulin resistance in colorectal carcinogenesis.

Logistic regression analysis showed that oral glucose tolerance test status, normal, impaired glucose tolerance, and diabetes mellitus did not show association with colorectal adenoma in this study. Several reports have shown that impaired glucose intolerance was associated with colorectal tumors (2, 36). These were large-scale studies for risks of colorectal cancer. Our findings may have been due to the small number of subjects. However, HOMA-IR index was associated with colorectal adenoma. Taken together with increased VFA and decreased plasma concentration of adiponectin, it seems that insulin resistance is associated with colorectal adenoma.

The number of colorectal adenomas and the size of the largest adenoma showed association with increased VFA and decreased plasma adiponectin in this study. Histologic progression from tubular adenoma to tubulovillous/villous adenoma was also associated with increased VFA and decreased plasma adiponectin. Much epidemiologic evidence has suggested that the insulin-like growth factor-I (IGF-I) axis is associated with colorectal cancer risk (37). The Physician's Health Study showed that after adjustment for age, cigarette smoking, BMI, alcohol intake, and IGF-I binding protein-3 levels, men in the top quintile of circulating IGF-I had a relatively higher risk compared with those in the bottom quintile (38). Results from the Flexi-Scope trial also showed that high IGF-I and low IGFBP-3 levels increased the probability of high-risk ademonas, defined as at least one adenoma ≥1 cm in diameter of tubulovillous or villous morphology or with severe dysplasia or the presence of three or more adenomas (39). Further study is needed to examine whether there is a straightforward relationship between VFA and IGF-I and IGFBP-3.

In conclusion, our findings suggest that increased VFA and decreased concentration of plasma adiponectin are associated with the development of colon adenoma in Japanese patients. However, as this study was done with a small number of patients, a large-scale study is needed to clarify the association of visceral fat accumulation and adiponectin with the development of colon adenoma and cancer. Similar studies are also needed with other ethnic groups, including Caucasians and other Asians. Such research may warrant an intervention study on whether reduction of visceral fat accumulation and plasma adiponectin by weight loss and exercise (40) can prevent further development of colorectal adenoma.


   Footnotes
 
Grant support: The 21st Century Center of Excellence Program of the Japan Society for the Promotion of Science grant-in-aid F-1 and Ministry of Education, Science, and Culture in Japan grant-in-aid 16046202.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/13/04; revised 11/24/04; accepted 12/ 7/04.


   References
Top
 Abstract
 Patients and Methods
 Results
 Discussion
 References
 

  1. Potter JD, Slatter ML, Bostick RM, et al. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993;15:499–545.[Free Full Text]
  2. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and indent colorectal cancer. J Natl Cancer Inst 1999;91:1147–54.[Abstract/Free Full Text]
  3. Giovannucci E, Aasherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327–34.[Abstract/Free Full Text]
  4. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987;36:54–9.[CrossRef][Medline]
  5. Matsuzawa Y. Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. Diabetes Metab Res Rev 1997;13:3–13.[CrossRef][Medline]
  6. Shuman WP, Newell-Morris LL, Leonetti DL, et al. Abnormal body fat distribution detected by computed tomography in diabetic men. Invest Radiol 1986;21:483–7.[Medline]
  7. Seidell JG, Oosterlee A, Thijssen MA, et al. Assessment of intra-abdominal and subcutaneous abdominal fat: relation between anthropometry and computed tomography. Am J Clin Nutr 1987;45:7–13.[Abstract/Free Full Text]
  8. Nieves DJ, Cnop M, Retzlaff B, et al. The atherogenic lipoprotein profile associated with obesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes 2003;52:172–9.[Abstract/Free Full Text]
  9. Kanai H, Tokunaga K, Fujioka S, et al. Decrease in intra-abdominal visceral fat may reduce blood pressure in obese hypertensive women. Hypertension 1996;27:125–9.[Abstract/Free Full Text]
  10. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79–83.[CrossRef][Medline]
  11. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595–9.[Abstract/Free Full Text]
  12. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23:85–9.[Abstract/Free Full Text]
  13. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002;51:2325–8.[Abstract/Free Full Text]
  14. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-{kappa}B signaling through a cAMP-dependent pathway. Circulation 2000;102:1296–301.[Abstract/Free Full Text]
  15. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003;107:671.[Abstract/Free Full Text]
  16. Engeli S, Feldpausch M, Gorzelniak K, et al. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003;52:942–7.[Abstract/Free Full Text]
  17. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003;88:993–7.[Abstract/Free Full Text]
  18. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;15:5699–704.
  19. The Expert Committee. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:11833–1197.
  20. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57–63.[Abstract]
  21. Tokunaga K, Matsuzawa Y, Ishikawa K, et al. A novel technique for determination of body fat by computed tomography. Int J Obes 1983;7:437–45.[Medline]
  22. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984;288:1401–4.
  23. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab 1982;54:254–60.[Abstract/Free Full Text]
  24. Folsom AR, Kaye SA, Sellers TA, et al. Body fat distribution and 5-year risk of death in older women [published erratum appears in JAMA 1993;269:1254]. JAMA 1993;269:483–87.[Abstract/Free Full Text]
  25. Sellers TA, Kushi LH, Potter JD, et al. Effect of family history, body-fat distribution, and reproductive factors on the risk of postmenopausal breast cancer [published erratum appears in N Engl J Med 1992;327:1612]. N Engl J Med 1992;326:1323–9.[Abstract]
  26. Gann PH, Daviglus ML, Dyer AR, et al. Heart rate and prostate cancer mortality: results of a prospective analysis. Cancer Epidemiol Biomarkers Prev 1995;4:611–6.[Abstract]
  27. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731–7.[CrossRef][Medline]
  28. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288–95.[CrossRef][Medline]
  29. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762–9.[CrossRef][Medline]
  30. Kern PA, Di Gregorio GB, Lu T, et al. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-{alpha} expression. Diabetes 2003;52:1779–85.[Abstract/Free Full Text]
  31. Goldfine AB, Kahn CR. Adiponectin: linking the fat cell to insulin sensitivity. Lancet 2003;362:1431–2.[CrossRef][Medline]
  32. Snehalathan C, Mukesh B, Simon M, et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003;26:3226–9.[Abstract/Free Full Text]
  33. Zietz B, Herfarth H, Paul G, et al. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003;19:103–4.
  34. Yokota T, Oritani K, Ishikawa J, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000;96:1723–32.[Abstract/Free Full Text]
  35. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer. J Clin Endocrinol Metab 2004;89:1102–7.[Abstract/Free Full Text]
  36. Nishii T, Kono S, Abe H, Eguchi H, et al. Glucose intolerance, plasma insulin levels, and colon adenomas in Japanese. Jpn J Cancer Res 2001;92:836–40.[CrossRef][Medline]
  37. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109–20S.
  38. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J Natl cancer Inst 1999;91:620–5.[Abstract/Free Full Text]
  39. Renehan AG, Painter JE, Atkin WS, et al. High-risk colorectal adenomas and serum insulin-like growth factors. Br J Surg 2001;88:107–13.[CrossRef][Medline]
  40. Kriketos AD, Gan SK, Poynten AM, et al. Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 2004;27:629–30.[Free Full Text]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. L. Schwartz, R. Malgor, E. Dickerson, A. T. Weeraratna, A. Slominski, J. Wortsman, N. Harii, A. D. Kohn, R. T. Moon, F. L. Schwartz, et al.
Phenylmethimazole Decreases Toll-Like Receptor 3 and Noncanonical Wnt5a Expression in Pancreatic Cancer and Melanoma Together with Tumor Cell Growth and Migration
Clin. Cancer Res., June 15, 2009; 15(12): 4114 - 4122.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H.-G. Moon, Y.-T. Ju, C.-Y. Jeong, E.-J. Jung, Y.-J. Lee, S.-C. Hong, W.-S. Ha, S.-T. Park, and S.-K. Choi
Visceral Obesity May Affect Oncologic Outcome in Patients with Colorectal Cancer
Ann. Surg. Oncol., July 1, 2008; 15(7): 1918 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. J Williams, N. Mitsiades, E. Sozopoulos, A. Hsi, A. Wolk, A.-P. Nifli, S. Tseleni-Balafouta, and C. S Mantzoros
Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors
Endocr. Relat. Cancer, March 1, 2008; 15(1): 289 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. N. Ealey, S. Lu, D. Lau, and M. C. Archer
Reduced susceptibility of muscle-specific insulin receptor knockout mice to colon carcinogenesis
Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G679 - G686.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. E. Drew, A. J. Farquharson, S. Padidar, G. G. Duthie, J. G. Mercer, J. R. Arthur, P. C. Morrice, and L. N. Barrera
Insulin, leptin, and adiponectin receptors in colon: regulation relative to differing body adiposity independent of diet and in response to dimethylhydrazine
Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G682 - G691.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L. Cong, J. Gasser, J. Zhao, B. Yang, F. Li, and A. Z Zhao
Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2
Endocr. Relat. Cancer, September 1, 2007; 14(3): 713 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
E. Giovannucci
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review
Am. J. Clinical Nutrition, September 1, 2007; 86(3): 836S - 842S.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. T. Campbell, M. Cotterchio, E. Dicks, P. Parfrey, S. Gallinger, and J. R. McLaughlin
Excess Body Weight and Colorectal Cancer Risk in Canada: Associations in Subgroups of Clinically Defined Familial Risk of Cancer
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1735 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
R. L. Sedjo, T. Byers, T. R. Levin, S. M. Haffner, M. F. Saad, J. A. Tooze, and R. B. D'Agostino Jr.
Change in Body Size and the Risk of Colorectal Adenomas
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 526 - 531.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
S.D.H. Malnick and H. Knobler
The medical complications of obesity
QJM, September 1, 2006; 99(9): 565 - 579.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Lukanova, S. Soderberg, R. Kaaks, E. Jellum, and P. Stattin
Serum Adiponectin is not Associated with Risk of Colorectal Cancer.
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 401 - 402.
[Full Text] [PDF]

Home page
 GutHome page
E E Frezza, M S Wachtel, and M Chiriva-Internati
Influence of obesity on the risk of developing colon cancer
Gut, February 1, 2006; 55(2): 285 - 291.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Otake, S.
Right arrow Articles by Kawata, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Otake, S.
Right arrow Articles by Kawata, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online